- Design
- Retrospective single-centre cohort with historical comparison
- Population
- 213 patients on brivaracetam, 891 serum samples
- Primary outcome
- Serum brivaracetam concentration by cenobamate dose
- Effect
- +32% at 12.5–50 mg/day (P=0.001); −21% at 250–450 mg/day (P<0.001)
Cenobamate inhibits CYP2C19, a pathway in brivaracetam metabolism, so an interaction was expected. This retrospective single-centre study at a German epilepsy centre analysed 891 routine serum brivaracetam levels from 213 patients, comparing those on cenobamate with a historical group not taking it, and adjusting for enzyme-inducing co-medication.
The interaction was biphasic. At low cenobamate doses (12.5–50 mg a day), brivaracetam concentrations were 32% higher (P = 0.001). At high doses (250–450 mg a day), they were 21% lower (P < 0.001). The likely explanation is CYP2C19 inhibition at low doses giving way to net induction of other pathways, such as CYP3A4, at higher doses.
This matters because cenobamate is titrated slowly over months, so a patient's brivaracetam exposure may first rise and then fall. The study did not measure seizures or adverse effects, the comparison group came from an earlier period, and individual variation will be large. But it argues for brivaracetam level monitoring, where available, across cenobamate titration rather than a single check.
- Watch for sedation or dizziness early in cenobamate titration in patients on brivaracetam.
- Watch for breakthrough seizures as cenobamate reaches higher doses.
- Consider brivaracetam levels at low and again at target cenobamate doses, where testing is available.
- Record cenobamate dose with each brivaracetam level to interpret it.
- Adjust brivaracetam on clinical response, not on the expected direction of the interaction alone.
Why it matters
It replaces a one-direction interaction warning with one that changes during titration.
Don't overread it
This retrospective study measured drug levels, not seizures or side effects, against a historical comparison group.
The statistics, in plain English
The 32% rise and 21% fall are average changes in serum concentration, adjusted for other enzyme-affecting drugs. Individual patients may differ much more, which is why measuring levels matters.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for clinical pharmacology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free